Truist analyst Joon Lee raised the firm’s price target on AnaptysBio to $30 from $20 but keeps a Hold rating on the shares. The firm is adjusting its model, stating the company deserves some credit for two pipeline programs about to read out Phase 2b data – one for atopic dermatitis in December and another for rheumatoid arthritis in Q1 of 2025, the analyst tells investors in a research note. Truis adds however that there is a fair amount of positive update already priced-in at this juncture.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio to sell 2.75M shares at $36.50 in registered direct offering
- Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
- AnaptysBio price target raised to $42 from $34 at Wedbush
- AnaptysBio reiterates cash runway through year-end 2026
- AnaptysBio reports Q2 EPS ($1.71), consensus (89c)